CLEARWATER – Two years ago, Morton Plant Hospital was the first in the Tampa Bay area to perform an advanced surgical procedure for severe symptomatic aortic stenosis called Transcatheter Aortic Valve Replacement (TAVR).
Now, Morton Plant Hospital is expanding its Valve Clinic and TAVR programs with another first, utilizing the newly FDA approved self-expanding Medtronic CoreValve.
Morton Plant is the first hospital in the country, not previously involved in the Medtronic research study, to implant the Medtronic CoreValve. The Heart Team at Morton Plant Hospital has now successfully completed six CoreValve implants. TAVR offers an alternative for patients with severe aortic stenosis, who are not considered candidates for conventional open heart surgery.
The CoreValve procedure is part of the legacy of firsts for the TAVR program since Morton Plant became the first hospital to bring the procedure to the Tampa Bay area two years ago.
“The difference with the CoreValve is that it provides an opportunity to treat a broader group of patients, including those with small valves, who previously may not have been able to have the procedure,” Joshua Rovin, M.D., a cardiovascular surgeon and a member of the Morton Plant Hospital Valve Clinic team, said in a press release.
“We hope that by utilizing leading edge TAVR treatment and technology, we can provide relief of symptoms, and improve the quality of life for more patients suffering from heart failure due to severe aortic stenosis,” said John Ofenloch, M.D., another cardiovascular surgeon and a member of the Morton Plant Hospital Valve Clinic team.
In January, the Food & Drug Administration approved the CoreValve. This means that patients do not have to be part of a clinical research trial to be considered, but still must meet FDA criteria.
The CoreValve is implanted through a thin, flexible tube (catheter), that is advanced through an artery in the groin (femoral artery), arm (subclavian artery), or via a small chest incision (aortic). The valve is then delivered inside the diseased natural aortic valve and allowed to expand.
“As more TAVR valves are approved, it provides additional resources that the Morton Plant Hospital Valve Clinic team can consider to treat patients who may not have been treatable before,” said Douglas Spriggs, M.D., an interventional cardiologist and a member of the Morton Plant Hospital Valve Clinic team.
“The TAVR procedure allows for the opportunity of a less invasive procedure, making it an option for patients who do not medically qualify for standard aortic valve replacement surgery,” said Lang Lin, M.D., another interventional cardiologist and a member of the Morton Plant Hospital Valve Clinic team. “Many factors are considered in the determination of the appropriate procedure for the treatment of advanced aortic valve disease. The valve clinic affords an opportunity for complex patients to be evaluated by an expert multidisciplinary team of physicians.”